Conditional sentence

Reliq Health Technologies, Inc. Announces Eight New US Contracts in Five States

Retrieved on: 
Tuesday, August 9, 2022 - 8:01am
WKN, RHT, CEO, GLOBE, Population, ER, Blockchain.com, Patient, Quality of life, Calendar, Frankfurt Stock Exchange, Company, Contract, OTC, TSX Venture Exchange, Conditional sentence, Health care, Hospital

The contracts are expected to add at least 5,000 new patients to Reliqs iUGO Care platform over the next three quarters.

Key Points: 
  • The contracts are expected to add at least 5,000 new patients to Reliqs iUGO Care platform over the next three quarters.
  • We are very pleased to be expanding into Idaho and New Mexico as well as growing our business in states where we already have a significant presence, said Dr. Lisa Crossley, CEO at Reliq Health Technologies, Inc.
  • Access to care is particularly challenging for chronic disease patients living in rural communities in these and other states.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.

Global Ultrasound Market Analysis/Growth Report 2022: Ultraportable Ultrasound Equipment Presenting Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 2:18pm
Radiology, Health, Medical Devices, Cardiology, Anesthesiology, Conditional sentence, Research, Solution, Obstetrics, Diagnosis, AI, Medical imaging

The "Global Ultrasound Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ultrasound Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research service examines the expansion of the use-cases of ultrasound for different disease areas and diagnostics as well as treatment.
  • The study will help ultrasound equipment providers understand the key trends emerging in the market (across different healthcare domains as well as geographic regions).
  • The research service also offers guidance for ultrasound vendors in terms of charting strategic priorities and building new capabilities to capitalize on the emerging growth opportunities in the ultrasound market.

Healthtab™ Expands With Shoppers Drug Mart®

Retrieved on: 
Monday, August 8, 2022 - 1:30pm
API, RWD, Biomarker, Pharmacy, GLOBE, Degenerative disease, Growth, Abbott, EGFR, Strep, Blood, Shoppers Drug Mart, Prediabetes, SOW, Patient, Glucose, COVID-19, Company, Master service agreement, Lipid, Glycated hemoglobin, Program, Conditional sentence, MSA, Pharmacist, Government, Diabetes, Government of Ontario, Health, Lipid profile, Medical device, Healthcare, Pharmaceutical industry

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Key Points: 
  • In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.
  • Announced in the summer of 2021 a signed MSA with Shoppers Drug Mart Inc. to pilot the HealthTab platform in 11 locations, allowing patients access to point-of-care blood screening and health-data management of potential risks for developing diabetes and cardiovascular conditions through the HealthTab-integrated Afinion 2 analyzers by Abbott Rapid Diagnostics.
  • HealthTab has already been deployed in 104 Shoppers Drug Mart pharmacies across British Columbia, New Brunswick, Nova Scotia and Ontario.
  • Approved tests include glucose, HbA1c and lipids, all of which HealthTab currently offers with the Abbott Afinion 2.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022 - 1:00pm
Stanford Institutes of Medicine Summer Research Program, Dermatology, Epigenetics, CEO, American Federation for Aging Research, Gene expression, Leadership, Stanford University, Disease, Coronavirus Scientific Advisory Board (Turkey), Research, Max Planck Institute for Molecular Biomedicine, Obstetrics, Quality of life, Cell, ERA, Stanford School, Conditional sentence, Ageing, Osteoarthritis, Epigenome, Doctor of Philosophy, Glossary, University, Science, Ophthalmology, Solution, Max Planck Society, AFAR, RNA transfection, Stanford University School of Medicine, Pharmaceutical industry, Vaccine, Sebastiano

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022 - 1:00pm
Stanford Institutes of Medicine Summer Research Program, Dermatology, Epigenetics, CEO, American Federation for Aging Research, Gene expression, Leadership, Stanford University, Disease, Coronavirus Scientific Advisory Board (Turkey), Research, Max Planck Institute for Molecular Biomedicine, Obstetrics, Quality of life, Cell, ERA, Stanford School, Conditional sentence, Ageing, Osteoarthritis, Epigenome, Doctor of Philosophy, Glossary, University, Science, Ophthalmology, Solution, Max Planck Society, AFAR, RNA transfection, Stanford University School of Medicine, Pharmaceutical industry, Vaccine, Sebastiano

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Global Telehealth Kiosk Market Outlook and Forecasts Report 2022-2027 Featuring Key Vendors - CSI Health, IDOCTORCLOUD, KIOSK Information, Olea Kiosk, & Sonka Medical - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 11:54am
Health, Telemedicine, Virtual Medicine, Death, Nursing, Telehealth, Vital signs, Risk, Patient satisfaction, Mental health, Population, Diagnosis, Investment, Hospital, Prevalence, Health, Patient, Time management, Emergency, COVID-19, Conditional sentence, Ageing, CAGR, APAC, Lists of countries and territories, Disease management, Medtech, Chronic condition, Weather, Solution, Pharmacy, Mental, Medicine, Heart failure, Developed country, Adoption, Healthcare, Medical device, Health insurance, Video game, Pharmaceutical industry

The global telehealth kiosk market is expected to grow at a CAGR of 19% during 2022-2027.

Key Points: 
  • The global telehealth kiosk market is expected to grow at a CAGR of 19% during 2022-2027.
  • Some key players in the telehealth kiosk market strive to combine customer suggestions for patient experience, patient satisfaction, and patient outcomes.
  • Stakeholders in the telehealth kiosk market are pushing these proposals to attract healthcare providers and patients.
  • Specialty-specific telehealth kiosk are also introduced in the market; Mental health telehealth kiosk have customized solutions for the patients.

U.S. Tele-Intensive Care Unit Market Outlook and Forecasts 2022-2027 Featuring Eagle Telemedicine, GE Healthcare, Hicuity, Health Intercept Telemed, Koninklijke Philips, SOC Telemed, & Teladoc Health - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 11:13am
Health, Health Technology, Chronic condition, Teladoc Health, Death, Jean-Louis Vincent, City, Telehealth, Vital signs, Risk, Disorder, Occupational burnout, Holiday, Mortality, Injury, InTouch, Mental health, Degenerative disease, Philips, Population, Technology, Cancer, Patient, ICU, Hospital, Prevalence, First Affiliated Hospital of Xinjiang Medical University, Industry, Critical care, Nursing, Intensive care unit, CDC, COVID-19, Ministry of Health (Saudi Arabia), Ageing, Ministry, Pandemic, Emergency, CAGR, Coronavirus, Diabetes, Hypertension, Conditional sentence, Solution, Bed, Efficiency, Adult, Medical imaging, Pharmaceutical industry, Healthcare, Animal, Medicine, Health

The U.S. Tele-Intensive Care Unit (ICU) market is expected to grow at a CAGR of 20.13% during 2022-2027.

Key Points: 
  • The U.S. Tele-Intensive Care Unit (ICU) market is expected to grow at a CAGR of 20.13% during 2022-2027.
  • In 2020, Teladoc Health, a key leader in virtual care, announced a $13.9 billion merger with Livongo.
  • Livongo brought facilities encouraging people with chronic conditions to live healthier lives, including diabetes prevention, hypertension, weight management, diabetes, and mental health.
  • In 2020, Teladoc Health also acquired InTouch, the leader in delivering scalable, incorporated virtual care solutions to health systems, hospitals, and other provider units, for a cumulative $1.1 billion.

BD, Direct Relief and National Association of Community Health Centers Advance Health Equity in the U.S. with $1 Million Grant

Retrieved on: 
Monday, August 8, 2022 - 11:50am
Food, Community health, Fortis Healthcare, Community, CEO, Mental health, Diagnosis, Poverty, Politics, Topical steroid withdrawal, Leadership, Becton, Dickinson and Company headquarters, A1C, Religion, Reconciliation (United States Congress), NACHC, Health equity, Patient, Emergency, Company, Twitter, BD, Therapy, Conditional sentence, Health, National Association, Safety, Direct Relief, Pharmacist, Diabetes, Solution, LinkedIn, Social determinants of health, Work, Housing, Efficiency, Medicine, Disease, Organization, Becton, Health insurance, Pharmaceutical industry, Hospital

FRANKLIN LAKES, N.J., Aug. 8, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC), today announced they have awarded four community health centers with a total of $1.08 million to implement programs to support chronic disease management to underserved communities.

Key Points: 
  • All four community health centers also received the Innovations in Care award in 2021.
  • "We are directly addressing these health inequities by investing in community health centers that help ensure underserved patients receive quality care.
  • "Private funding partnerships made possible by BD and Direct Relief are essential to support innovative approaches that health centers bring to foster wellness and health equity in underserved communities."
  • Established in 1971, the National Association of Community Health Centers (NACHC) serves as the leading national voice for America's Health Centers and as an advocate for health care access for the medically underserved and uninsured.

Global Medical Aesthetics Market to Reach $31.6 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 10:55am
Health, Other Health, Bausch Health, Industry, Population, Growth, Trauma, Medical tourism, Burn, CAGR, Conditional sentence, Adoption, Dentistry, Industrial design, Tissue paper, Cynosure

The "Medical Aesthetics Market - Global Industry Analysis (2019 - 2021) - Growth Trends and Market Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Aesthetics Market - Global Industry Analysis (2019 - 2021) - Growth Trends and Market Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The report expects global medical aesthetics market valuation to reach beyond US$31.6 Bn toward the end of 2027, pointing to the elevated prospects of digital aesthetics, and advanced techniques.
  • Key Highlights into Global Medical Aesthetics Market:
    Liposuction to remain the most sought-after offering in medical aesthetics market, accounting for an estimated revenue share of around 18% by 2027
    Increasing conscious of consumers about their physical appearance has been elevating the prospects of medical aesthetics worldwide.
  • With the boom around digital aesthetics growing denser, the market for medical aesthetics will witness a significant hike.

Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility

Retrieved on: 
Monday, August 8, 2022 - 6:00am
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, PIK, Fatty liver disease, Tranche, CEO, IPF, EUR, Prospectus, Board, Annual, AMF, Adrenoleukodystrophy, Euronext Paris, NASH, Company, Program, Partnership, Conditional sentence, Shareholder, Lists of diseases, Earnings before interest, taxes, depreciation and amortization, Solution, Pharmaceutical industry, Security (finance), Bank, Director, Euronext

We have thus been working diligently these past months to extend our cash runway to capitalize on this opportunity and independently finance our strategy in rare diseases.

Key Points: 
  • We have thus been working diligently these past months to extend our cash runway to capitalize on this opportunity and independently finance our strategy in rare diseases.
  • The Company has entered into an agreement with IPF to restructure its debt, resulting in the postponement of the Q3 2022 and Q4 2022 amortization payments under the existing debt facility, and lowering certain financial covenants until the end of January 2023.
  • The Company is actively pursuing additional financing options, prioritizing non-dilutive sources, including ongoing active partnership discussions related to its programs.
  • The amendment of the debt facility also includes an increase of 3% of the PIK margin (in addition to the existing 2% PIK).